Systemic Lupus Erythematosus - Clinical Aspects: New Therapies

Session Type: ACR Abstract Submissions
Tuesday, November 8, 2011: 2:30 PM-4:00 PM
W183a (McCormick Place West)
SessionSelect
Moderators: Sandra Navarra, University of Santo Tomas Hospital and C. Aranow, MD, Feinstein Institute for Medical Research
Papers:
2:30 PM
Efficacy and Safety of Abatacept Over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study
Richard Furie1, Kathy Nicholls2, Tien-Tsai Cheng3, Frederic Houssiau4, Ruben Burgos-Vargas5, Shun-Le Chen6, Richard Aranda7, Stephanie Meadows-Shropshire8, Michael Kinaszczuk8 and Joan T. Merrill9, 1North Shore-Long Island Jewish Health System, Lake Success, NY, 2Royal Melbourne Hospital, Victoria, Australia, 3Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 4Cliniques Universitaires Saint-Luc, Brussels, Belgium, 5Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, 6Joint Molecular Rheumatology Laboratory of Institute of Health Sciences and Shanghai Ren Ji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7Bristol-Myers Squibb [at time of study], Princeton, NJ, 8Bristol-Myers Squibb, Princeton, NJ, 9Oklahoma Medical Research Foundation, Oklahoma City, OK
2:45 PM
Active Immunization Against IFNα with IFN-Kinoid in SLE Patients Is Safe, Immunogenic and Induces Down-Regulation of IFN-Mediated Genes
Frédéric A. Houssiau1, Raskov Rashkov2, Eric Hachulla3, Estibaliz Lazaro4, Christian Jorgensen5, François Spertini6, Xavier Mariette7, Géraldine Grouard-Vogel8, Bernard Fanget8, Olivier Dhellin8, Bernard Lauwerys1 and Pierre Vandepapelière8, 1Université catholique de Louvain, Brussels, Belgium, 2MHAT Sveti Ivan Rilski, Sofia, Bulgaria, 3Internal Medicine, Lille CEDEX, France, 4Hôpital Haut-Lévêque, Pessac, France, 5Hospital Lapeyronie, Montpellier, France, 6CHU Vaudois, Lausanne, Switzerland, 7Université Paris-Sud, Le Kremlin Bicetre, France, 8NEOVACS SA, Paris, France
3:00 PM
Omega-3 in Systemic Lupus Erythematosus: A Double-Blind, Placebo-Controlled Randomized Clinical Trial In Systemic Lupus Erythematosus
Kayode J. Bello1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD
3:15 PM
Effect of Belimumab Treatment on Renal Outcomes: Results From Phase 3 Belimumab Clinical Trials in Patients with Systemic Lupus Erythematosus
M.A. Dooley1, F. Houssiau2, C. Aranow3, D.P. D'Cruz4, Anca D. Askanase5, D. Roth6, Z.J. Zhong7, W. Freimuth7, E.M. Ginzler8 and BLISS-52/-76 Study Groups9, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Université catholique de Louvain, Brussels, Belgium, 3Feinstein Institute for Medical Research, Manhasset, NY, 4St. Thomas' Hospital, London, United Kingdom, 5NYU School of Medicine, New York, NY, 6GlaxoSmithKline, King of Prussia, PA, 7Human Genome Sciences, Inc., Rockville, MD, 8SUNY-Downstate Medical Center, Brooklyn, NY, 9Multicenter
3:30 PM
Allogeneic Mesenchymal Stem Cells Transplantation in Severe and Refractory Systemic Lupus Erythematosus-Four Years Follow up
Lingyun Sun, Dandan Wang, Huayong Zhang, Xia Li and Xuebing Feng, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
3:45 PM
Abatacept for Lupus Nephritis: Alternative Outcome Measures Support Opposing Interpretations of Data From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study
David Wofsy, VA Medical Center, San Francisco, CA, Stephanie Meadows Shropshire, Bristol-Myers Squibb, Richmond, VA, Jan L. Hillson, ZymoGenetics Inc., Seattle, WA and Betty Diamond, Feinstein Institute Med Rsch, Manhasset, NY
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.